Path ID: DB08922_MESH_D012559_1
Concepts
| Identifier | Name | Type |
|---|---|---|
| MESH:C065533 | perospirone | Drug |
| UniProt:P28223 | 5-hydroxytryptamine receptor 2A | Protein |
| UniProt:P14416 | D(2) dopamine receptor | Protein |
| UniProt:P08908 | 5-hydroxytryptamine receptor 1A | Protein |
| GO:0014046 | dopamine secretion | BiologicalProcess |
| GO:0014047 | glutamate secretion | BiologicalProcess |
| GO:0004952 | dopamine neurotransmitter receptor activity | MolecularActivity |
| CHEBI:18243 | dopamine | ChemicalSubstance |
| UBERON:0009834 | dorsolateral prefrontal cortex | GrossAnatomicalStructure |
| UBERON:0001910 | medial forebrain bundle | GrossAnatomicalStructure |
| HP:0100543 | Cognitive impairment | PhenotypicFeature |
| HP:0030213 | Emotional blunting | PhenotypicFeature |
| HP:0012154 | Anhedonia | PhenotypicFeature |
| HP:0002465 | Poor speech | PhenotypicFeature |
| HP:0000741 | Apathy | PhenotypicFeature |
| HP:0000709 | Psychosis | PhenotypicFeature |
| HP:0000739 | Anxiety | PhenotypicFeature |
| MESH:D012559 | Schizophrenia | Disease |
Relationships
NOTE: predicates are annotated in Biolink Model (v1.3.0)
| Subject | Predicate | Object |
|---|---|---|
| Perospirone | INCREASES ACTIVITY OF | 5-Hydroxytryptamine Receptor 1A |
| Perospirone | DECREASES ACTIVITY OF | D(2) Dopamine Receptor |
| Perospirone | DECREASES ACTIVITY OF | 5-Hydroxytryptamine Receptor 2A |
| 5-Hydroxytryptamine Receptor 1A | NEGATIVELY CORRELATED WITH | Anxiety |
| 5-Hydroxytryptamine Receptor 2A | POSITIVELY REGULATES | Dopamine Secretion |
| 5-Hydroxytryptamine Receptor 2A | POSITIVELY REGULATES | Glutamate Secretion |
| Glutamate Secretion | POSITIVELY CORRELATED WITH | Dopamine Neurotransmitter Receptor Activity |
| Dopamine Neurotransmitter Receptor Activity | POSITIVELY CORRELATED WITH | Psychosis |
| D(2) Dopamine Receptor | POSITIVELY REGULATES | Dopamine Secretion |
| Dopamine Secretion | INCREASES ABUNDANCE OF | Dopamine |
| Dopamine | LOCATED IN | Medial Forebrain Bundle |
| Medial Forebrain Bundle | CORRELATED WITH | Psychosis |
| Psychosis | POSITIVELY CORRELATED WITH | Schizophrenia |
| Dopamine | LOCATED IN | Dorsolateral Prefrontal Cortex |
| Dorsolateral Prefrontal Cortex | CORRELATED WITH | Cognitive Impairment |
| Dorsolateral Prefrontal Cortex | CORRELATED WITH | Emotional Blunting |
| Dorsolateral Prefrontal Cortex | CORRELATED WITH | Anhedonia |
| Dorsolateral Prefrontal Cortex | CORRELATED WITH | Poor Speech |
| Dorsolateral Prefrontal Cortex | CORRELATED WITH | Apathy |
| Cognitive Impairment | MANIFESTATION OF | Schizophrenia |
| Emotional Blunting | MANIFESTATION OF | Schizophrenia |
| Anhedonia | MANIFESTATION OF | Schizophrenia |
| Poor Speech | MANIFESTATION OF | Schizophrenia |
| Apathy | MANIFESTATION OF | Schizophrenia |
| Anxiety | MANIFESTATION OF | Schizophrenia |
Comment: The action of the drug on 5-HT2 receptors is of an inverse agonist (https://en.wikipedia.org/wiki/Inverse_agonist). The dopamine neurons are located in the mesolimbic dopaminergic system (BTO:0005591), which is a component pathway of the medial forebrain bundle (UBERON:0001910)(https://en.wikipedia.org/wiki/Medial_forebrain_bundle#Anatomy).
Reference:
- https://go.drugbank.com/drugs/DB08922#mechanism-of-action
- https://en.wikipedia.org/wiki/Antipsychotic#Mechanism_of_action
- https://en.wikipedia.org/wiki/Mesolimbic_pathway#Relation_to_neurological_and_psychological_disorders
- https://en.wikipedia.org/wiki/Schizophrenia#Signs_and_symptoms
- https://en.wikipedia.org/wiki/Dopaminergic_pathways#Pathways
- https://en.wikipedia.org/wiki/Mesocortical_pathway
- https://en.wikipedia.org/wiki/Dopamine_hypothesis_of_schizophrenia#Introduction
- https://en.wikipedia.org/wiki/Atypical_antipsychotic#Pharmacology
- https://en.wikipedia.org/wiki/5-HT1A_receptor#Function